Editorial Commentary: Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: "We're Gonna Need a Bigger Boat"
- PMID: 27624957
- PMCID: PMC5146721
- DOI: 10.1093/cid/ciw639
Editorial Commentary: Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: "We're Gonna Need a Bigger Boat"
Keywords: CRE; Enterobacteriaceae; antibiotic resistance; carbapenem-resistance; ceftazidime-avibactam.
Comment on
-
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.Clin Infect Dis. 2016 Dec 15;63(12):1615-1618. doi: 10.1093/cid/ciw636. Epub 2016 Sep 13. Clin Infect Dis. 2016. PMID: 27624958 Free PMC article.
References
-
- Spellberg B, Shlaes D. Prioritized current unmet needs for antibacterial therapies. Clin Pharmacol Ther 2014; 96:151–3. - PubMed
-
- Antibiotic resistant threats in the United States, 2013. US Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013.... Accessed 15 August 2016.
-
- Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60:913–20. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical